Table 1: Baseline characteristics and outcomes for 171 HIV-infected patients receiving ART and either rifabutin of rifampicin for treatment of tuberculosis.

	Groups	Rifabutin N=41 % (n)	Rifampicin N=130 % (n)	p value ^a
Variable				
Baseline				
Age	Median [IQR], years	37.0 [32.4, 43.0]	35.9 [32.0, 43.0]	0.553*
Sex	Female	34.1 (14)	43.8 (57)	0.272
	Male	65.9 (27)	56.2 (73)	
Ethnic origin	White	39.0 (16)	23.1 (30)	0.003
	Black	41.5 (17)	70.0 (91)	
	Other	19.5 (8)	6.9 (9)	
HIV transmission	Homosexual	36.6 (15)	19.2 (25)	0.051
	Heterosexual	53.7 (22)	73.1 (95)	
	IVDU	9.8 (4)	7.7 (10)	
Hospital attended	Chelsea & Westminster	63.4 (26)	50.8 (66)	0.031
	University College London	36.6 (15)	49.2 (64)	
Type of ART	NNRTI	22.0 (9)	100.0 (130)	-
	PI	78.0 (32)	0.0 (0)	
Had TB in the past	No	92.7 (38)	90.0 (117)	0.764**
	Yes	7.3 (3)	10.0 (13)	
Type of TB Diagnosis	Confirmed	82.9 (34)	79.2 (103)	0.605
	Presumptive	17.1 (7)	20.8 (27)	
Time between HIV & TB diagnosis	Median [IQR], months	58 [3,108]	8 [0,54]	0.001*
Site of TB	Pulmonary	70.7 (29)	73.1 (95)	0.878**
	Lymph node	19.5 (8)	16.2 (21)	
	Disseminated	9.8 (4)	10.8 (14)	
Outcomes of treatment	•		, ,	
Duration of TB treatment	Median [IQR], months	6 [6,9]	6 [6,9]	0.634*
Completed TB regimen	Yes	87.8 (36)	96.9 (126)	0.037**
	No	12.2 (5)	3.1 (4)	
TB Treatment Interruption	Yes	25.0 (10)	17.7 (23)	0.307
	No	75.0 (30) ^b	82.3 (107)	
IRIS	Yes	29.3 (12)	12.3 (16)	0.012
	No	70.7 (29)	87.6 (112)°	
Change in CD4 count at end	Median [IQR], cells/mm ³	75	70	0.781*
of TB treatment		[-12,241]	[8,170]	
HIV VL at end of TB	Undetectable	87.5 (35)	78.6 (99)	0.256**
treatment	Detectable	12.5 (5)	21.4 (27) ^d	
Died by end of treatment	Yes	2.4 (1)	2.3 (3)	1.000**

Key: ^a χ^2 test unless specified: *Mann-Whitney U test: ** Fisher's exact test: ^b outcome not recorded for one patient: ^c outcome not recorded for two patients: ^d plasma HIV viral load result not available for one patient: IQR =interquartile range: IVDU =injecting drug user: ART =antiretroviral therapy: NNRTI =non-nucleoside reverse transciptase inhibitor: PI =protese inhibitor: IRIS =immune reconstitution inflammatory syndrome: VL =plasma HIV viral load.